Endeavour Medtech Growth II LP closes at $375m

The fund will pursue the strategy to support innovative growth-stage medtech and digital health companies.Both new and returning investors supported EMG II LP, including public pension funds, multi-manager funds, family offices and high-net-worth individuals.

The fund’s closing comes as the world begins to look towards post-pandemic life after more than 12 months in the grip of COVID-19, a crisis that has accelerated the adoption of new healthcare technologies including novel ways of delivering remote patient care, wearables etc. Underlying trends, such as ageing populations, chronic diseases and strained healthcare budgets will continue to fuel demand for cost-efficient solutions. Therefore, healthcare innovation is set to remain a long-term priority that is expected to generate attractive growth and a diverse set of opportunities for investors.

The fund has already supported seven companies with investments of more than US$100 million: IntelyCare, CeQur, Rapid Micro Biosystems, SOPHiA GENETICS, Nalu Medical, Lumeon and Relievant Medsystems.